SCHEMBL679392

SCHEMBL679392

Nc1ccc(Oc2cc3cnn(C4CCCCO4)c3cc2C(=O)NC2CCOCC2)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 5/20 0.41
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
MAPK14 Q16539 5/20 0.37
STK10 O94804 1/20 0.37
CSF1R P07333 1/20 0.37
RET P07949 1/20 0.37
PDGFRB P09619 1/20 0.37
KIT P10721 1/20 0.37
FLT1 P17948 1/20 0.37
TIE1 P35590 1/20 0.37
FLT4 P35916 1/20 0.37
FLT3 P36888 1/20 0.37
TEK Q02763 1/20 0.37
MERTK Q12866 1/20 0.37
KDM1A O60341 2/20 0.37
BMPR1B O00238 1/20 0.37
BMPR1A P36894 1/20 0.37
TGFBR1 P36897 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679563 0.88 ALDH1A1 (0.38) AXLRXRARXRBRXRGMAPK14
SCHEMBL680860 0.85 RXRA (0.43) RXRARXRBRXRGMAPK14GAK
SCHEMBL680688 0.81 RXRB (0.44) AXLRXRARXRBRXRGMAPK14
SCHEMBL680086 0.76 RXRA (0.43) AXLRXRARXRBRXRGRET
SCHEMBL679190 0.75 RXRA (0.43) RXRARXRBRXRGMAPK14MAPK1
SCHEMBL680363 0.75 ATR (0.40) RXRARXRBRXRGMAPK14
SCHEMBL680225 0.74 RXRA (0.43) RXRARXRBRXRGMAPK14GAK
SCHEMBL680135 0.71 RXRA (0.40) RXRARXRBRXRGMAPK14
SCHEMBL2144678 0.70 ALDH1A1 (0.50) RXRARXRBRXRGMAPK14RET
SCHEMBL30442483 0.70 ALDH1A1 (0.50) RXRARXRBRXRGMAPK14RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC AXL 113/4885RXRA 4592/4885RXRB 4066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.